November 2008 - Page 61 of 76

MondayNov 03, 2008 4:54 am

PhotoMedex, Inc. (NASDAQ: PHMD)

PhotoMedex, Inc. (NASDAQ: PHMD) provides novel solutions designed for application in the areas of dermatology, therapeutic skin care and surgical products & services. The company is currently developing proprietary excimer laser and fiber-optic systems to treat dermatological applications such as psoriasis and vitiligo. PhotoMedex’s XTRAC® was the first FDA market-cleared excimer laser system designed to treat dermatological applications such as psoriasis and vitiligo. For further information, visit the Company's web site at www.photomedex.com.

MondayNov 03, 2008 4:54 am

PharmAthene, Inc. (AMEX: PIP)

PharmAthene, Inc. (AMEX: PIP) is focused on addressing the critical needs of the United States and its allies through the development and commercialization of medical countermeasures against biological and chemical weapons. Currently, the company’s lead product development programs include: SparVax, an anthrax vaccine; a third generation rPA anthrax vaccine; Valortim, an antibody designed to prevent and treat anthrax infection; Protexia, a bioscavenger; and RypVax, a dual antigen vaccine for plague. For further information, visit the Company's web site at www.pharmathene.com.

MondayNov 03, 2008 4:54 am

Capstone Therapeutics (NASDAQ: CAPS)

Capstone Therapeutics (NASDAQ: CAPS), a biotechnology company, is focused on developing a pipeline of innovative therapeutic peptides designed to help patients with under-served medical conditions. The Company is currently committed to developing and commercializing two product platforms: AZX100 and Chrysalin® (rusalatide acetate or TP508). AZX100 is currently under evaluation for commercially significant medical applications such as treating pulmonary disease, and Chrysalin is currently under evaluation for treating disorders that involve vascular endothelial dysfunction. For further information, visit the Company's web site at www.capstonethx.com.

MondayNov 03, 2008 4:53 am

Pharmasset, Inc. (NASDAQ: VRUS)

Pharmasset, Inc. (NASDAQ: VRUS), a clinical-stage pharmaceutical company, is focused on discovering, developing and commercializing innovative drugs for the treatment of viral infections. The company’s primary focus is on developing of oral therapeutics for the treatment of hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV). Their product candidates include: Clevudine (for treating chronic HBV infection), R7128 (for treating HCV), and R7128 (for treating HIV). For further information, visit the Company's web site at www.pharmsset.com.

MondayNov 03, 2008 4:53 am

Capitol Acquisition Corporation (AMEX: CLA)

Capitol Acquisition Corporation (AMEX: CLA) is a blank check company formed for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, one or more operating businesses or assets. Located in Washington, DC, Capitol is led by their CEO Mark D. Ein. For further information, visit the company website at: www.venturehousegroup.com.

MondayNov 03, 2008 4:53 am

Pharmacopeia, Inc. (NASDAQ: PCOP)

Pharmacopeia, Inc. (NASDAQ: PCOP), a clinical development stage biopharmaceutical company, is focused on discovering and developing innovative small molecule therapeutics to attend to significant medical needs. The company’s broad portfolio of clinical and preclinical candidates are currently under development internally or with partners, including nine clinical compounds in Phase 2 or Phase 1 development. For further information, visit the Company's web site at www.pcop.com.

MondayNov 03, 2008 4:52 am

Petro Resources Corporation (AMEX: PRC)

Petro Resources Corporation (AMEX: PRC), an independent exploration and production company, is focused on acquiring exploratory leases, producing properties, and secondary enhanced oil recovery projects as well as exploratory drilling and production of oil and natural gas in the United States. The company’s aim is to create and maximize shareholder value by leveraging the expertise of its management team with industry partners to grow a diversified portfolio of oil and natural gas producing projects and prospects. For further information, visit the Company's web site at www.petroresourcescorp.com.

MondayNov 03, 2008 4:52 am

Candax Energy Inc. (TSX: CAX CN)

Candax Energy Inc. (TSX: CAX CN), a Toronto-based oil and natural gas company, is focused on exploring, acquiring, developing and producing natural gas and crude oil, with emphasis on the Middle East and Africa. The company has concentrated their efforts on Tunisia and holds an interest in an exploration permit in Madagascar. Candax was founded by highly skilled executives and successful Canadian founders and financiers to develop an international upstream oil and gas asset portfolio. For further information, visit the Company's web site at www.candax.com.

MondayNov 03, 2008 4:51 am

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM)

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical stage biopharmaceutical company, is committed to developing novel monoclonal antibodies to treat cancer and hepatitis C virus (HCV) infection. The company is currently progressing three distinct clinical programs, bavituximab and Cotara® being its leading product candidates, both of which are in Phase II clinical studies for the treatment of cancer. Additionally, bavituximab is in a Phase I clinical study for the treatment of HCV infection. For further information, visit the Company's web site at www.peregrineinc.com.

MondayNov 03, 2008 4:51 am

CanAlaska Uranium Ltd. (TSX: CVV CN)

CanAlaska Uranium Ltd. (TSX: CVV CN) is focused on exploring for uranium in the Athabasca Basin of Saskatchewan, Canada. This region contains the world's richest and most profitable uranium deposits, and has accounted for one-third of the world’s global uranium supply and contributed 25% of global production in 2007. The company’s team is led by Dr. Karl Schimann, a veteran Athabasca uranium geologist who was a senior member of the team that discovered the prolific Cigar Lake Mine (grading 20% U3O8) in 1981. For further information, visit the Company's web site at www.canalaska.com.

Site Search

Company Search

Month: November 2008

PhotoMedex, Inc. (NASDAQ: PHMD)

PharmAthene, Inc. (AMEX: PIP)

Capstone Therapeutics (NASDAQ: CAPS)

Pharmasset, Inc. (NASDAQ: VRUS)

Capitol Acquisition Corporation (AMEX: CLA)

Pharmacopeia, Inc. (NASDAQ: PCOP)

Petro Resources Corporation (AMEX: PRC)

Candax Energy Inc. (TSX: CAX CN)

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM)

CanAlaska Uranium Ltd. (TSX: CVV CN)

Market Basics

Newsletter Publishers

Public Companies